Zevra Therapeutics (ZVRA) Competitors

Sarepta Therapeutics (NASDAQ:SRPT) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Is SRPT or ZVRA more profitable?

Zevra Therapeutics has a net margin of 4.33% compared to Sarepta Therapeutics' net margin of -2.34%. Sarepta Therapeutics' return on equity of -1.03% beat Zevra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-2.34%	-1.03%	-0.37%
Zevra Therapeutics	4.33%	-112.40%	-37.67%

Which has more risk & volatility, SRPT or ZVRA?

Sarepta Therapeutics has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500. Comparatively, Zevra Therapeutics has a beta of 1.87, suggesting that its share price is 87% more volatile than the S&P 500.

Do analysts prefer SRPT or ZVRA?

Sarepta Therapeutics presently has a consensus target price of $43.50, suggesting a potential upside of 117.22%. Zevra Therapeutics has a consensus target price of $23.71, suggesting a potential upside of 149.49%. Given Zevra Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Zevra Therapeutics is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	6 Sell rating(s)	15 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.07
Zevra Therapeutics	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	3.00

Which has better earnings and valuation, SRPT or ZVRA?

Sarepta Therapeutics has higher revenue and earnings than Zevra Therapeutics. Zevra Therapeutics is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$2.48B	0.79	$235.24M	-$0.87	-23.02
Zevra Therapeutics	$23.61M	22.60	-$105.51M	-$0.21	-45.26

Does the media favor SRPT or ZVRA?

In the previous week, Sarepta Therapeutics had 37 more articles in the media than Zevra Therapeutics. MarketBeat recorded 65 mentions for Sarepta Therapeutics and 28 mentions for Zevra Therapeutics. Sarepta Therapeutics' average media sentiment score of 0.23 beat Zevra Therapeutics' score of 0.14 indicating that Sarepta Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sarepta Therapeutics	6 Very Positive mention(s)	9 Positive mention(s)	45 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zevra Therapeutics	5 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Do insiders and institutionals hold more shares of SRPT or ZVRA?

86.7% of Sarepta Therapeutics shares are held by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are held by institutional investors. 7.6% of Sarepta Therapeutics shares are held by company insiders. Comparatively, 2.4% of Zevra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Sarepta Therapeutics beats Zevra Therapeutics on 9 of the 16 factors compared between the two stocks.